RDHL - RedHill Biopharma Ltd.
| Previous Close | 7.04 |
| Open | 7.07 |
| Bid | 6.97 x 800 |
| Ask | 7.13 x 1000 |
| Day's Range | 6.95 - 7.18 |
| 52 Week Range | 5.13 - 11.49 |
| Volume | 47,149 |
| Avg. Volume | 52,335 |
| Market Cap | 203.951M |
| Beta (3Y Monthly) | 2.51 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- American City Business Journals•22 days ago
She left one Triangle public company to become CSO of another local public pharma
Just months after exiting a leadership position at another Triangle public company, one career researcher has been tapped as the CSO of another.
- American City Business Journals•last month
Israeli firms ramps up in Raleigh as drug nears approval
On the eve of filing for FDA approval of its lead drug, RedHill executives say the company is already building up its executive team in the Triangle.
- American City Business Journals•6 months ago
RedHill closes $20M public offering to prep commercialization of new drug
RedHill Biopharma just closed on a $20 million public offering to fund the commercial launch of its drug, Talicia – which means expansion of the company's Raleigh team.
- Reuters•7 months ago
RedHill Biopharma's antibiotic succeeds in late-stage study
Israel-based RedHill Biopharma Ltd said on Monday its combination antibiotic met the main goal of a late-stage study testing the drug in patients with a type of bacterial infection that affects the stomach and small intestine. The drug, Talicia, eradicated the Helicobacter pylori infection in 84 percent of patients, compared with 58 percent that received a combination of two commonly used antibiotics. RedHill estimates 2.5 million patients are treated annually for H. pylori bacterial infections in the United States.
- Zacks•7 months ago
IntelGenx's NDA Resubmission for Rizaport Gets FDA Acceptance
The FDA accepts IntelGenx's (IGXT) NDA resubmssion for its migraine candidate Rizaport 10 mg. The stock appreciates.
- Zacks•10 months ago
What's in the Offing for Keysight (KEYS) in Q3 Earnings?
Keysight's (KEYS) focus on launching new solutions for growth markets like 5G, IoT, next-generation wireless, high-speed datacenters and automotive & energy bodes well for its top-line.
- Zacks•11 months ago
Medical-Drugs Stock Outlook: No Respite from Near-Term Pain
Medical-Drugs Stock Outlook: No Respite from Near-Term Pain
- Motley Fool•11 months ago
Why Redhill Biopharma Ltd. Stock Is Soaring Today
Redhill's late-stage Crohn's disease drug hits the mark in a late-stage trial.
- Benzinga•11 months ago
RedHill Earns Long-Awaited Boost On Positive Crohn's Data
REDHILL BIOPHAR/S ADR (NASDAQ: RDHL ) achieved positive top-line results in its Phase 3 study of RHB-104 in Crohn’s disease, according to a Monday press release . What Happened The drug met both primary ...
- Reuters•11 months ago
RedHill BioPharma has positive results from Crohn's disease trial
Israel's RedHill Biopharma said on Monday it had positive safety and efficacy results from a late-stage clinical trial with its treatment for Crohn's disease called RHB-104. The study met its primary endpoint and key secondary endpoints, demonstrating the drug's superiority over a placebo in achieving remission of the gastrointestinal disease at week 26, the company said in a statement. "The proportion of patients meeting the primary endpoint was significantly greater in the RHB-104 group compared to placebo," RedHill said.
- Zacks•11 months ago
RedHill Gets Two New Patents for Crohn's Disease Candidate
RedHill Biopharma (RDHL) announces allowances of two new patents from the United States Patent and Trademark Office and the European Patent Office for its Crohn's disease candidate, RHB-104.
- Zacks•last year
RedHill Biopharma (RDHL) Catches Eye: Stock Jumps 5.4%
RedHill Biopharma (RDHL) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
- Zacks•last year
RedHill Biopharma (RDHL): Moving Average Crossover Alert
RedHill Biopharma Ltd. (RDHL) is looking like an interesting pick from a technical perspective
